Alpha Endeavour takes the stage three times at Discovery & Development US 2026
Our CEO, Ed Addison, speaks three times at Discovery & Development US 2026, hosted by Oxford Global at the Hilton San Diego Bayfront on 12–13 October. It is Alpha Endeavour's first panel appearance.
1. Closed-door investor panel
Where Smart Capital Meets Science: Investing in the Next Wave of Drug Discovery Innovation. Day 1, 12 October, 15:05–15:30. Ed sits on this closed-door investor panel in Track 4 – Start-Ups, Closed Door Sessions & Round Table Discussions.
2. Industry presentation
Multi-Agentic AI for Drug Discovery and Development. Day 1, 12 October, 12:25–12:50, Track 2 – AI-Guided Medicinal & Computational Chemistry. AI for drug discovery has largely focused on individual tasks such as target identification and molecular design. A major limitation of many approaches is that they remain point solutions, addressing only one part of the drug discovery and development process. Ed's talk explores how multi-agent AI systems can integrate many specialised tasks into one coordinated, end-to-end approach to drug discovery and development.
3. Panel: The Target Validation Frontier
The Target Validation Frontier: Multi-Omics and AI in Drug Discovery. Day 1, 12 October, 14:40–15:05, Conference Room 1, Track 1 Part 1 – Target Identification & Validation. Ed joins Pablo Tamayo (Professor, Division of Genomics & Precision Medicine, UCSD School of Medicine) and Xiaoguang Li (Team & Program Leader, Senior Scientist II, Immunology Research Discovery, AbbVie) to discuss standardising and integrating omics data across platforms and labs, balancing computational prediction with experimental validation, and where AI fits in multi-omics pipelines.